Replies to post #10029 on PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

I had previously posted as a comparison another company testing metformin delivered in the gut in a delayed fashion where it decreases systemic effects but still stimulates release of GLP-1 and related effects to lower blood sugar in type 2 diabetes. Interestingly, they presented some phase 2b study findings at the same 2013 annual meeting of European Association for Study of Diabetes (EASD) where Dr. Rojas presented the Sucanon study in Latino prediabetics. The link below outlines some further progress in phase 2b just announced in November 2016. They are a private company but have millions upon millions in venture capital signed on. Just some food for thought as we await the Sucanon trial results vs metformin, the most widely prescribed oral medication worldwide, and gold standard first line treatment per ADA.

http://elcelyx.com/wp-content/uploads/2015/06/EASD-Curtain-Raiser-FINAL.pdf

By the way, their product is most assuredly not a fraud either, and I see more than a few similarities in terms of timing and scientific potential. Beyond that, reading the article link above shows the following:

1. The researcher presenting at EASD 2013, MD, PhD, is an advisor to the company Elcelyx.
2. Their announcement does not say how much he or the several other advisors listed on their website are compensated.
3. By the logic previously employed here, those advisors are unethical, frauds, or (insert your own disparaging name here) and the drug is fraudulent snake oil (after all, it is not approved by FDA) and the company is promoting a health and financial scam to the world.
4. Alternatively, as I have posted repeatedly, an advisor or consultant relationship is permitted and is disclosed with presentation or publication of research.
5. Additionally, no quote is included in their news release from the research institution or the presenting researcher, Dr Baer.

I've obviously used some sarcasm to make my points here, but by all means, read for yourselves and evaluate some of the similarities and potential of both companies, and above all, note why the oral formulation of Metformin is being studied in the first place (to decrease the systemic absorption and thus side effects, particularly concerning for patients with impaired renal (kidney) function.